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Abstract
Virulent strains of Pseudomonas aeruginosa are often associated with an acquired cytotoxic
protein, exoenzyme U (ExoU) that rapidly destroys the cell membranes of host cells by its
phospholipase activity. Strains possessing the exoU gene are predominant in eye infections
and are more resistant to antibiotics. Thus, it is essential to understand treatment options for
these strains. Here, we have investigated the resistance profiles and genes associated with
resistance for fluoroquinolone and beta-lactams. A total of 22 strains of P. aeruginosa from
anterior eye infections, microbial keratitis (MK), and the lungs of cystic fibrosis (CF) patients
were used. Based on whole genome sequencing, the prevalence of the exoU gene was
61.5% in MK isolates whereas none of the CF isolates possessed this gene. Overall, higher
antibiotic resistance was observed in the isolates possessing exoU. Of the exoU strains, all
except one were resistant to fluoroquinolones, 100% were resistant to beta-lactams. 75%
had mutations in quinolone resistance determining regions (T81I gyrA and/or S87L parC)
which correlated with fluoroquinolone resistance. In addition, exoU strains had mutations at
K76Q, A110T, and V126E in ampC, Q155I and V356I in ampR and E114A, G283E, and
M288R in mexR genes that are associated with higher beta-lactamase and efflux pump
activities. In contrast, such mutations were not observed in the strains lacking exoU. The
expression of the ampC gene increased by up to nine-fold in all eight exoU strains and the
ampR was upregulated in seven exoU strains compared to PAO1. The expression of mexR
gene was 1.4 to 3.6 fold lower in 75% of exoU strains. This study highlights the association
between virulence traits and antibiotic resistance in pathogenic P. aeruginosa.
Introduction
Pseudomonas aeruginosa infections can be severe in people with a compromised immune sys-
tem and impaired anatomical structures caused by, for example burns, cystic fibrosis or
mechanical abrasions [1]. P. aeruginosa is a successful opportunistic pathogen in part due to
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its production of a diverse repertoire of pathogenic factors and its innate ability to evade the
host immune system [2]. Treatment of P. aeruginosa infections can be challenging due to the
inherent antibiotic resistance, where some studies have shown that half of the isolates from
clinical infections were resistant to antibiotics [3]. Furthermore, reports on co-selection of
antibiotic resistance and pathogenic factors indicate that antibiotic resistance may be a factor
for the evolution of more virulent strains of P. aeruginosa or vice versa [4–13].
Many Gram-negative bacteria, including P. aeruginosa, possess type III secretion systems
(TTSS), which they utilise to introduce virulence factors directly into host cells [14]. In P. aeru-
ginosa, TTSS transports four secreted factors: ExoU, ExoS, ExoY and ExoT. However, all of
these factors may not be common in all P. aeruginosa strains. For example, the exoS gene was
present in 58–72%, the exoU gene in 28–42%, the exoY gene in 89% and the exoT gene in 92–
100% of isolates from acute infections [15]. Pathogenic strains contain either exoU or exoS, but
rarely both [16, 17]. The exoU gene is associated with a genomic island and its acquisition may
cause loss of the exoS [18, 19]. The exoU gene encodes a cytotoxic protein that rapidly destroys
the cell membranes of mammalian cells by its phospholipase activity [19]. The presence of
exoU correlates with phenotypes that are responsible for the severe outcome of many infec-
tions including pneumonia [20] and keratitis [21]. Up to two-thirds of ocular isolates of P. aer-
uginosa possess the exoU gene [22], which is a much higher rate than the isolates from other
infections [6, 23, 24].
The frequency of antibiotic resistance of the exoU gene carrying strains is higher than that
of exoS-strains; [5, 10] the reason for this higher frequency remains undefined. P. aeruginosa
strains with the exoU gene tend to harbour mutations in quinolone resistance determining
regions (QRDRs) that lead to fluoroquinolone resistance [5, 9]. Whilst it is known that strains
of P. aeruginosa can possess mutations in resistance determining regions affecting beta-latam
susceptibility, such as the chromosomal beta-lactamase gene (ampC), its transcriptional regu-
lator (ampR) [25] and a repressor gene (mexR) that negatively regulates expression of an active
efflux pump (MexAB-OprM) [26], the correlation between the exoU carriage and mutations in
drug resistance determining regions has not been extensively examined.
We hypothesised that possession of the exoU gene correlates with mutations not only in
QRDRs but also in beta-lactam resistance determining regions. The aim of this study was to
examine the correlation between the virulent genotypes (exoS vs. exoU) and resistance to beta-
lactam and fluoroquinolone antibiotics in P. aeruginosa strains. Furthermore, we examined
the relative expression of specific genes to confirm their role in antibiotic resistance.
Materials and methods
Bacterial isolates and antibiotic susceptibility testing
Twenty-two P. aeruginosa strains isolated from anterior eye infections, microbial keratitis
(MK), or lungs of cystic fibrosis patients from India and Australia were used in this study
(Table 1). The minimum inhibitory concentrations (MICs) of ceftazidime (Sigma-Aldrich,
Inc., St. Louis, MO, USA), cefepime (European Pharmacopoeia, Strasbourg, France) aztreo-
nam (Sigma-Aldrich, Inc), ticarcillin (Sigma-Aldrich, Inc), imipenem (Sigma-Aldrich, Inc),
levofloxacin (Sigma-Aldrich, Inc), ciprofloxacin (Sigma-Aldrich, Inc), and moxifloxacin
(European Pharmacopoeia) were determined by the broth microdilution method as described
by the Clinical and Laboratory Standards Institute (CLSI) [27]. The MIC was taken as the low-
est concentration of an antibiotic in which no noticeable growth (turbidity) was observed [28]
and the break point was established according to published standards [29, 30]. Both resistant
and intermediate resistant strains were considered here as resistant.
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DNA extraction and sequencing
Bacterial DNA was extracted from overnight cultures grown on Trypticase Soy Agar (TSA;
Oxoid Ltd., Basingstoke, UK), using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Ger-
many) following the manufacturer’s instructions. The extracted DNA was sequenced on
MiSeq (Illumina, San Diego, CA, USA) platform generating 300 bp paired-end reads. The
paired-end library was prepared using Nextera XT DNA library preparation kit (Illumina, San
Diego, CA, USA). All of the libraries were multiplexed on one MiSeq run. Genome assembly
and annotations were performed using SPAdes version 3.11.1 [31] and Prokka version 1.7
[32]. BLAST search was performed to investigate carriage of exoU and exoS genes. All nucleo-
tide sequences were deposited in NCBI GenBank data base under Bio-project accession num-
ber PRJNA431326.
Sequence analysis and variant calling
The mutations in selected resistance genes (gyrA, gryB, parC, parE, mexR, ampC, ampD and
ampR) of each strain were determined with reference to P. aeruginosa PAO1 (Genbank RefSeq
accession no. NC_002516.2). Briefly, the reference genome was mapped to the paired-end
reads for each isolate using Bowtie2 version 2.3.2 [33] and the variants were compiled and
annotated using SAMtools, version 1.7 [34] and SnpEff version 4.3 [35]. The QRDRs were
assigned to amino acid positions 83 to 87 of the GyrA protein, positions 429 to 585 of the
GyrB protein, positions 82 to 84 of the ParC protein, and positions 357 to 503 of the ParE pro-
tein [36]. For ampC variants, mutations different from common polymorphisms (G27D,
Table 1. Strains and origin of Pseudomonas aeruginosa used in this study.






















PAO1 Reference strain [64] (RefSeq accession no. NC_002516.2)
MK = Microbial keratitis, CF = Cystic fibrosis
https://doi.org/10.1371/journal.pone.0204936.t001
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R79Q, T105A, Q156R, L176R, V205L, and G391A), which are present in both susceptible and
non-susceptible strains [37] were considered here. Mutations in mexR or ampR were consid-
ered as significant for resistance from previous literature [38–40].
Total RNA extraction and qRT-PCR analysis
Strains were revived from frozen stocks into 5 mL Trypticase Soy Broth (TSB; Oxoid) and
grown to mid-exponential phase (OD660 1.5) and 1 ml was centrifuged at 6000 g for 3 min to
harvest the cells. The pellet was mixed with 1 mg/ml lysozyme in Tris-EDTA buffer (TE; 10
mM Tris-hydrochloride and 1.0 mM EDTA pH 8.0) to lyse the cells. RNA extraction was per-
formed using the ISOLATE RNA Mini Kit (Bioline, London, UK) following the manufacturer
instructions for RNA isolation from bacteria. The RNA extract was treated with DNase1 (Bio-
line) to eliminate the DNA contamination and purified by ethanol precipitation [41]. RNA
purity and concentration was measured by NanoDrop spectrophotometer (ND-1000, Thermo-
Fisher, MA, USA). cDNA was synthesized from 1 μg of total RNA using SuperScript First-Strand
synthesis system for RT-PCR (Invitrogen, Carlsbad, CA, USA) employing random primers and
following the manufacturer’s protocol. Quantitative PCR was performed with a PowerUp SYBR
Green Master Mix (Applied Biosystems, Austin, TX, USA), using 96 well optical plates (Micro-
Amp Fast Optical, Applied Biosystems) following the manufacturer’s instructions and cycle con-
ditions. A 7500 Fast Real-Time PCR System (Applied Biosystems) was used to measure the
expression levels of the target DNA sequences using gene specific primers (Table 2). The relative
expression levels were quantified using the comparative CT method [42] to obtain the fold
change in each gene with reference to the respective genes of P. aeruginosa PAO1, which does
not carry the exoU gene. A house keeping gene, rpsL encoding the 30S ribosomal protein S12,
was used as an internal expression control for normalisation. The experiments were carried out
three times in triplicate and the mean and standard deviations were calculated.
Results
Possession of exoU/exoS and antibiotic resistance
BLAST search showed that of the 22 isolates, 8 out of the 13 eye isolates (62%) possessed the exoU
gene, while it was absent from the cystic fibrosis (CF) isolates (Fig 1B). Except for a CF strain
(PA57) which lacked both exoU and exoS genes, all strains that lacked the exoU gene carried the
exoS gene and none of the studied strains harboured both genes. For the exoS strains, 8/13 showed
a medium level (2–16 μg/ml) of resistance to at least one fluoroquinolone and 8/13 were resistant
to at least one beta-lactam, mostly ticarcillin (Fig 1A). Six of these eight strains were resistant to
Table 2. Primers used in this study.







ampC Cephalosporinase CGGCTCGGTGAGCAAGACCTTC–F 22 264 218 [46]
AGTCGCGGATCTGTGCCTGGTC–R 22 481
mexR Transcriptional regulator CGCGAGCTGGAGGGAAGAAACC–F 22 217 150 [46]
CGGGGCAAACAACTCGTCATGC–R 22 366
ampR Transcriptional regulator TGCTGTGTGACTCCTTCGAC–F 20 215 160 This Study
AGATCGATGAAGGGATGGCG–R 20 374
rpsL 30S ribosomal protein S12 (house keeping
gene)
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both a fluoroquinolone and beta-lactam. All except one (PA175) exoU strain were resistant to at
least two tested fluoroquinolones with MICs of between 2–128 μg/ml with six strains having32
for ciprofloxacin. All the exoU strains were resistant to at least three beta-lactams except for
PA175, which was only resistant to ticarcillin and imipenem (Fig 1B, 1C and 1D).
Mutations in target genes of QRDRs and possession of exoU
Mutations in four different QRDRs were examined with reference to P. aeruginosa PAO1. Of
the strains containing exoU, 6/8 had a T83I mutation in gyrA and 5/8 had combined mutations
in both gyrA (T83I) and parC (S87L); none of the exoS strains had either of these mutations.
Strains with mutations in gyrA or parC were resistant to all three fluoroquinolones and these
mutations correlated with higher MICs for fluoroquinolones (Table 3). None of the exoS
strains possessed mutations in gyrA and parC. However, mutations were observed in gyrB and
parE in five exoS-strains which were associated with higher MIC to fluoroquinolones
(Table 3). Interestingly, no mutations in gyrB or parE were found in the exoU strains. It should
be noted that five strains (PA82, PA17, PA40, PA100 and PA171) had no mutations in any of
these genes, but were resistant to at least one fluoroquinolone, although resistance tended to
be8 μg/ml, except PA82 which had an MIC of 64 μg/ml for ciprofloxacin.
Mutations associated with beta-lactam antibiotics and exoU
This study also examined mutations in cephalosporinase (ampC) and its regulator (ampR) and
the efflux pump MexAB-OprM regulator (mexR). A number of mutations were seen in ampC,
Fig 1. Antibiotic susceptibility patterns and possesion of exoU and exoS genes. A) Antibiotic susceptibility pattern
of exoU and exoS strains. Both resistant and intermediate resistant strains were considered here as resistant. Black
boxes represent resistance and white boxes represent susceptibility. B) Number of microbial keratitis (MK) and cystic
fibrosis (CF) isolates that carry exoU or exoS genes. C) susceptibility of exoU and exoS strains to fluoroquinolones. D)
susceptibility of exoU and exoS strains and to beta-lactams. [CIP = ciprofloxacin, LEVO = Levofloxacin,
MOX = Moxifloxacin, CFT = ceftazidime, CEF = cefepime, TIC = ticarcillin, IMI = imipenem, AZT = Aztreonam].
https://doi.org/10.1371/journal.pone.0204936.g001
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but only those mutations that have been previously reported to be significant contributors to
resistance were considered here (all observed mutations are shown in S1 Table). Variation in
amino acid position V356I was common in six exoU strains, Q155R was found in strain PA82
and no significant mutations were observed in PA34. Such mutations were, however absent in
exoS-strains. Similarly, all of the exoU strains had a common mutation in the in mexR gene at
amino acid position 126, changing valine to glutamic acid, in addition to mutations at A110T
in PA34 and K76Q in PA175. Such mutations were not present in the exoS strains. Further-
more, all the exoU strains had various mutations (E114A, G283E, and M288R) in the ampR
gene, but only one exoS strain (PA171) had mutations in this gene and this at position 244.
The susceptibility results showed that possession of such mutations was associated with higher
MICs to various beta-lactams, except for strain PA175 which had all these mutations in mexR,
ampC, and ampR genes but was sensitive to cefepime and ceftazidime (Table 4).
Expression analysis of ampC, ampR and mexR genes
The relative expression of ampC, ampR and mexR genes in all of the exoU strains and three
randomly selected exoS strains (PA55, PA86 and PA149) were compared to P. aeruginosa
PAO1 to analyse the effect of such mutations on expression (Fig 2). The relative expression of
Table 3. Mutations in the quinolone resistance determining region of P. aeruginosa and the MIC of fluoroquinolones.
Strain Genes MIC (μg/ml) of Fluoroquinolones
gyrA gryB parC parE CIP LEVO MOX
exoU strains PA31 T83I S87L 32 32 64
PA32 T83I S87L 64 32 128
PA33 T83I S87L 128 32 64
PA34 2 2 8
PA35 T83I S87L 64 32 128
PA37 T83I S87L 64 32 128
PA82 64 4 4
PA175 T83I 0.25 0.25 1
exoS strains PA17 2 1 8
PA40 4 2 2
PA55 1 0.5 4
PA59 0.125 0.25 1
PA64 A473V 8 16 16
PA66 E468D 2 4 8
PA86 L457-458A 0.5 1 2
PA92 S466F A473V 4 4 16
PA100 2 1 8
PA102 A473V 2 4 8
PA149 0.5 0.5 2
PA157 0.25 0.5 2
PA171 4 2 8
PAO1 0.25 0.25 1
The numbers denote change in amino acid positions when compared with the genome of P. aeruginosa PAO1.
Bold = resistant or intermediate resistant.
CIP = ciprofloxacin, LEVO = Levofloxacin, MOX = Moxifloxacin.
Insertion and frameshift variant.
 Reference strain
https://doi.org/10.1371/journal.pone.0204936.t003
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the ampC was two to nine fold higher in all of the exoU strains and was slightly lower in all
three exoS strains compared to PAO1. Similarly, the relative expression of the ampR was at
least two fold higher for five out of eight exoU strains. For an exoU strain (PA33), the ampR
gene was repressed six fold. The expression of mexR gene was repressed in six exoU strains
while overexpression of mexR was observed in two exoS strains relative to PAO1.
Discussion
The exoU gene is commonly found in P. aeruginosa strains isolated from contact lens-related
microbial keratitis, at frequencies of 46–54%, [11] whereas it only occurs in 0–14% of non-ocu-
lar isolates [6, 22–24]. Similar to a previous report, [10] exoU+ strains in the current study had
higher resistance to beta-lactams than exoS+ strains (100% exoU strains vs. 61% exoS strains
were resistant to at least one beta-lactam). ExoU secreting P. aeruginosa had more mutations
in genes that are associated with beta-lactam resistance (mexR, ampC and ampR) than did exoS
+ strains. Gene expression analysis suggested that such mutations generally lead to antibiotic
resistance, as the expression of ampC and ampR generally increased while the expression of
mexR was decreased, compared to the sensitive strain PAO1.
Several in vivo and in vitro studies have shown that the exoU carrying P. aeruginosa is asso-
ciated with severe outcome of diseases [7, 12, 20, 21, 43, 44]. In additions, results of this and
Table 4. Mutations in beta-lactam resistance determining regions and beta lactam resistance profiles.
Strains Genes MIC (μg/ml) towards beta-lactams
mexR ampC ampR CFT CEF TIC IMI AZT
exoU strains PA31 V126E V356I G283E, M288R 16 16 64 4 16
PA32 V126E V356I G283E, M288R 16 8 64 4 32
PA33 V126E V356I G283E, M288R 32 16 128 8 8
PA34 A110T, V126E E114A, G283E, M288R 4 32 >128 16 8
PA35 V126E V356I G283E, M288R 16 32 128 8 16
PA37 V126E V356I G283E, M288R 16 8 64 4 8
PA82 V126E Q155I G283E >128 >128 32 1 8
PA175 K76Q, V126E V356I G283E, M288R 2 4 64 4 8
exoS strains PA17 4 4 128 1 8
PA40 1 2 64 4 8
PA55 32 64 32 4 8
PA59 2 2 16 1 8
PA64 16 64 32 1 4
PA66 16 64 32 0.25 8
PA86 4 8 64 1 8
PA92 32 64 8 1 1
PA100 4 8 16 2 0.5
PA102 1 1 16 0.5 4
PA149 2 4 16 1 4
PA157 2 4 16 1 4
PA171 R244W 2 1 32 4 8
PAO1 1 1 16 1 4
The numbers denote change in amino acid positions when compared with the genome of P. aeruginosa PAO1.
Bold = resistance or intermediate resistance.
CFT = ceftazidime, CEF = cefepime, TIC = ticarcillin, IMI = imipenem, AZT = Aztreonam.
Reference strain
https://doi.org/10.1371/journal.pone.0204936.t004
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other studies confirmed that exoS+ and exoU+ strains have different antibiotic resistance pat-
terns [10, 45]. Therefore, they may require different treatment strategies. Knowing the viru-
lence gene profiles, the clinical outcome of the patients the resistance patterns might be
predicted, and this information could be used in deciding appropriate antibiotic treatment.
A mutation at amino acid position 126 (changing valine to glutamic acid) in MexR was
common in all exoU+ strains. Underexpression of mexR has been associated with antibiotic
resistance in P. aeruginosa [46]. Mutations in mexR contribute to the over-expression of the
MexAB-OprM efflux pump, [47, 48] which in turn is specific to increased resistance to beta-
lactams [49]. The current study demonstrated that mutation in mexR was correlated with
lower transcription of this gene in 75% of exoU+ strains. The higher expression of mexR in
exoS+ strains observed here appears to support the hypothesis that possession of the exoU gene
is associated with beta-lactam resistance.
Various different mutations in ampC and ampR between exoU and exoS subpopulations
were revealed in the current study. Mutations in ampC and ampR were more common in exoU
+ strains. Berrazeg et al [37] demonstrated that mutations in ampC at amino acid positions
G27D, R79Q, T105A, Q156R, L176R, V205L, and G391A were not correlated with beta-lactam
resistance and hence were excluded here from analysis in the current study. Mutations at
amino acid positions Q155I and V356I in ampC were observed in exoU+ strains, and all these
Fig 2. Expression of cephalosporinase (ampC) its regulator (ampR) and the efflux pump MexAB-OprM regulator (mexR) in strains. The relative expression
levels were compared to Pseudomonas aeruginosa PAO1 (widetype, non-exoU strain) and are presented as fold change in gene expression. Error bars represent
standard deviation of the mean fold change.
https://doi.org/10.1371/journal.pone.0204936.g002
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strains had increased gene expression of ampC, suggesting that these mutations may be
responsible for this reduced expression. A few exoS+ strains and one exoU+ strain (PA34) did
not have such mutations but were resistant to some beta-lactams. Point mutations in ampR (at
114, 182, 283, and 288) can also be responsible for beta-lactam resistance [38] and exoU+ strain
PA34 carried mutations at E114A and G283E. Mutations at G283E and M288R in ampR were
exclusive to exoU+ strains. These mutations were correlated with over-expression of ampC
and ampR in exoU+ strains. The precise mechanism by which acquisition of the exoU associ-
ated genomic island results in these mutations is not known. For resistance of exoS+ strains, it
is possible that beta-lactam resistance involves other resistance mechanisms, such as the upre-
gulation of efflux systems MexCD-OprJ, MexEF-OprN, and MexXY-OprM, [50] and hence
requires further study for elucidation.
Possession of exoU was also associated with higher MICs to fluoroquinolones compared to
possession of exoS, and this has been shown in previous studies [5, 10, 45, 51–53]. Mutations
in the QRDRs of target genes topoisomerase II (gryA and gyrB) and topoisomerase IV (parC
and parE) have been previously shown to increase fluoroquinolone resistance in P. aeruginosa
[54, 55]. Here, it was also observed that fluoroquinolone resistance in exoU strains was corre-
lated with a combination of mutations in gyrA and parC. Sequence analysis indicated that six
out of eight exoU strains had at least one mutation in either gyrA (T83I) or parC (S87L). Con-
sistent with other studies, [54, 56] such mutations were responsible for very high MICs to fluo-
roquinolones. This suggests the possibility that more virulent strains of P. aeruginosa that have
the exoU gene may evolve in the clinical environment where high concentrations of fluoro-
quinolones are used for treatment; for example, in eye infections [57, 58]. The conditions that
favour selection of exoU+ strains might result in increased resistance to other antibiotics. In
addition, this study also detected several mutations in QRDRs in the exoS+ population. Muta-
tions at position E468D of gyrB and A473V of parE were associated with increase MICs to all
tested fluoroquinolones. Such mutations have been previously associated with fluoroquinolone
resistance P. aeruginosa [59, 60]. It appears that different types of mutations in QRDRs evolved
in the exoU+ and exoS+ strains.
An exoS+ strain (PA55) was resistant to all beta lactams except aztreonam but no mutations
were observed in the studied genes and expression of genes did not correlate with phenotypic
resistance. Furthermore, an exoU+ strain (PA82) did not have any mutations in QRDRs but
was resistant to ciprofloxacin and levofloxacin. However, mutations in V126E the mexR of
PA82 has been associated with resistance to fluoroquinolone [26, 61]. The evidence from the
current study suggests that mutations A110T (PA34) and K76Q (PA175) in mexR may confer
susceptibility to ceftazidime even in presence of the V126E mutation. This needs to be con-
firmed by further study.
In addition, we observed a link between the exoU and the origin of the strains in India
because only one Australian strain (PA175) possessed the exoU gene and the resistance rate
was higher in the cohort of Indian strains. However, it should be noted that the possession of
exoU is highly correlated with antibiotic resistance in P. aeruginosa regardless of source and
geographical site of isolation [5, 9, 10, 13, 45]. ExoU+ strains may have an evolutionary advan-
tage by having the potential to be both more resistant and more virulent. This is supported by
a study that showed higher prevalence of the exoU in isolates collected from the hospital envi-
ronment [62]. A correlation between the geographic origin and the exoU carriage was observed
in this study potentially due to the relatively unregulated use of antibiotics in India compared
to Australia [63]. However, these observations require confirmation with a larger sample size
that should include isolates from various sources and a study of associated epidemiological
data.
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In conclusion, exoU carrying strains, which are common in ocular isolates, showed differ-
ent antibiotic resistance pattern from isolates with exoS genotype. The exoS+ strains may be
protected from the action of antibiotics due to their ability to cause mammalian cells to ingest
them (so-called invasive strains). Their residence inside mammalian cells may offer protection
from antibiotics and so diminish selection pressure to convert to antibiotic resistance. The
exoU+ strains had more mutations in drug resistance determining genes (gyrA, parC, mexR,
ampC and ampR), which was likely to be the cause of higher antibiotic resistance in exoU
+ strains. Differences in mutational rate in two different virulent genotypes indicate more vir-
ulent strains can favourably be evolved in the antibiotic rich environment. Therefore, under-
standing of both virulence traits and antibiotic resistance is essential for more effective
prevention of antibiotic resistance.
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